India Pharma Outlook Team | Thursday, 11 June 2026
AstraZeneca received approval for Enhertu Expansion in India as the company received regulatory approval for the expanded use of its breast cancer drug Enhertu.
The approval from the Central Drugs Standard Control Organisation (CDSCO) is expected to widen access to the treatment for eligible patients and strengthen AstraZeneca's oncology portfolio in the country.
The Enhertu expansion in India marks an important development for both cancer care and AstraZeneca Pharma India's growth strategy.
The latest approval allows broader use of Enhertu (trastuzumab deruxtecan), a targeted therapy developed by AstraZeneca and Daiichi Sankyo. The move comes as demand for advanced cancer treatments continues to grow in India, where breast cancer remains one of the most commonly diagnosed cancers among women.
AstraZeneca Pharma India informed exchanges that the CDSCO has approved an expanded indication for Enhertu in the treatment of breast cancer. The approval enables healthcare professionals to use the drug for a wider patient population based on the approved indication.
Enhertu is an antibody-drug conjugate (ADC), a type of targeted cancer treatment that combines a HER2-directed antibody with a chemotherapy agent. The therapy is designed to deliver treatment directly to cancer cells while limiting damage to healthy tissues.
Also Read: Indian CDMO 2.0 Guide: Risk-Sharing and Hybrid Models
The latest regulatory clearance is expected to improve access to innovative cancer treatment for patients who may benefit from the therapy. Clinical studies have shown that Enhertu can help improve treatment outcomes in certain breast cancer patients.
The approval is also significant from a business perspective. Expanding the approved use of a drug can increase its potential patient base and support future revenue growth. Oncology remains one of AstraZeneca's key focus areas globally, and the company has been investing heavily in cancer research and treatment innovation.
Industry experts believe that wider adoption of advanced targeted therapies could help improve cancer care standards in India. The approval also reflects the growing importance of precision medicine in oncology treatment.
The expanded approval further strengthens AstraZeneca Pharma India's position in the oncology segment. The company has been actively building its cancer treatment portfolio through innovative therapies across multiple indications.
While the approval is a positive development, the actual commercial impact will depend on factors such as pricing, patient access, physician adoption, and market penetration. Nevertheless, the approval provides AstraZeneca with an opportunity to expand its presence in the fast-growing oncology market.
Investors are likely to keep a close watch on the adoption of Enhertu and its contribution to the company's future performance.
AstraZeneca Pharma India Limited is the Indian subsidiary of AstraZeneca, a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. The company operates across key therapeutic areas including oncology, cardiovascular, renal, metabolism, respiratory, and rare diseases.
.jpg)
